1-[(3-氟苯基)甲基]苯并咪唑-2-胺 | 99138-83-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-[(3-氟苯基)甲基]苯并咪唑-2-胺
• 英文名称: 1-(3-fluorobenzyl)-2-aminobenzimidazole
• 英文别名: 1-[(3-fluorophenyl)methyl]-1H-benzimidazol-2-amine；1-[(3-fluorophenyl)methyl]benzimidazol-2-amine
• CAS: 99138-83-7
• 化学式: C₁₄H₁₂FN₃
• mdl: MFCD11202289
• 分子量: 241.268
• InChiKey: IGTREIYZVKUTSY-UHFFFAOYSA-N

物化性质

• 沸点：
  448.9±47.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-甲基-2-噻吩甲醛 、 1-[(3-氟苯基)甲基]苯并咪唑-2-胺 以 正丁醇 为溶剂， 以24.5%的产率得到
  参考文献：
  名称：

  A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling

  摘要：

  Background and PurposeRecent development in drug discovery have shown benzimidazole to be an important pharmacophore,. Benzimidazole derivatives exhibit broad‐spectrum pharmacological properties including anti‐microbial, anti‐diabetic and anti‐tumour activity. However, whether benzimidazole derivatives are effective in suppressing angiogenesis and its underlying mechanisms remain incompletely understood. In this study, we aim to characterize the anti‐angiogenic mechanisms of a novel 2‐aminobenzimidazole‐based compound, Jzu 17, in an effort to develop novel angiogenesis inhibitor.Experimental ApproachEffects of Jzu 17 on endothelial cell proliferation, migration, invasion, and activation of signalling molecules induced by VEGF‐A, were analysed by immunoblotting, MTT, BrdU, migration, and invasion assays. We performed tube formation assay, aorta ring sprouting assay, matrigel plug assay, and a mouse model of metastasis to evaluate ex vivo and in vivo anti‐angiogenic effects of Jzu 17.Key ResultsJzu 17 inhibited VEGF‐A‐induced cell proliferation, migration, invasion, and endothelial tube formation of HUVECs. Jzu 17 suppressed VEGF‐A‐induced microvessel sprouting ex vivo and attenuated VEGF‐A‐ or tumour cell‐induced neovascularization in vivo. Jzu 17 also reduced B16F10 melanoma lung metastasis. In addition, Jzu 17 inhibited the phosphorylation of VEGFR‐2 and its downstream signalling molecules in VEGF‐A‐stimulated HUVECs. Results from computer modelling further showed that Jzu 17 binds to VEGFR‐2 with high affinity.Conclusions and ImplicationsJzu 17 may inhibit endothelial remodelling and suppress angiogenesis through targeting VEGF‐A‐VEGFR‐2 signalling. These results also suggest Jzu 17 as a potential lead compound and warrant the clinical development of similar agents in the treatment of cancer and angiogenesis‐related diseases.

  DOI：

  10.1111/bph.14813
• 作为产物：
  描述：

  2-氨基苯并咪唑 、 间氟氯苄 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 6.0h， 以70.8%的产率得到1-[(3-氟苯基)甲基]苯并咪唑-2-胺
  参考文献：
  名称：

  A novel 2‐aminobenzimidazole‐based compound Jzu 17 exhibits anti‐angiogenesis effects by targeting VEGFR‐2 signalling

  摘要：

  Background and PurposeRecent development in drug discovery have shown benzimidazole to be an important pharmacophore,. Benzimidazole derivatives exhibit broad‐spectrum pharmacological properties including anti‐microbial, anti‐diabetic and anti‐tumour activity. However, whether benzimidazole derivatives are effective in suppressing angiogenesis and its underlying mechanisms remain incompletely understood. In this study, we aim to characterize the anti‐angiogenic mechanisms of a novel 2‐aminobenzimidazole‐based compound, Jzu 17, in an effort to develop novel angiogenesis inhibitor.Experimental ApproachEffects of Jzu 17 on endothelial cell proliferation, migration, invasion, and activation of signalling molecules induced by VEGF‐A, were analysed by immunoblotting, MTT, BrdU, migration, and invasion assays. We performed tube formation assay, aorta ring sprouting assay, matrigel plug assay, and a mouse model of metastasis to evaluate ex vivo and in vivo anti‐angiogenic effects of Jzu 17.Key ResultsJzu 17 inhibited VEGF‐A‐induced cell proliferation, migration, invasion, and endothelial tube formation of HUVECs. Jzu 17 suppressed VEGF‐A‐induced microvessel sprouting ex vivo and attenuated VEGF‐A‐ or tumour cell‐induced neovascularization in vivo. Jzu 17 also reduced B16F10 melanoma lung metastasis. In addition, Jzu 17 inhibited the phosphorylation of VEGFR‐2 and its downstream signalling molecules in VEGF‐A‐stimulated HUVECs. Results from computer modelling further showed that Jzu 17 binds to VEGFR‐2 with high affinity.Conclusions and ImplicationsJzu 17 may inhibit endothelial remodelling and suppress angiogenesis through targeting VEGF‐A‐VEGFR‐2 signalling. These results also suggest Jzu 17 as a potential lead compound and warrant the clinical development of similar agents in the treatment of cancer and angiogenesis‐related diseases.

  DOI：

  10.1111/bph.14813

文献信息

• [EN] BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF<br/>[FR] BENZIMIDAZOLES ET AZA-BENZIMIDAZOLES ET LEURS MÉTHODES D'UTILISATION
  申请人：GOLDFINCH BIO INC

  公开号：WO2019028308A1

  公开（公告）日：2019-02-07

  Disclosed are compounds according to Formula (I) or (II), and pharmaceutical compositions comprising them. Also disclosed are therapeutic methods, e.g., of treating kidney diseases, using the compounds of Formula (I) or (II). (Formulae (II), (III))

  根据公式（I）或（II）披露了化合物，以及包含它们的药物组合物。还披露了治疗方法，例如使用公式（I）或（II）的化合物治疗肾脏疾病。（公式（II），（III））
• Anti-allergic five membered heterocyclic ring containing N-(bicyclic
  申请人：Janssen Pharmaceutica, N.V.

  公开号：US04634704A1

  公开（公告）日：1987-01-06

  Five membered heterocyclic ring containing N-(bicyclic heterocyclyl)-4-piperidinamines having histamine and serotonine antagonistic activity which compounds are useful agents in the treatment of allergic diseases.

  含有N-(双环杂环基)-4-哌啶胺基的五元杂环环，具有组胺和5-羟色胺拮抗活性的化合物，这些化合物是治疗过敏病的有用药剂。
• Kinase Inhibitors
  申请人：Bonjouklian Rosanne

  公开号：US20080227839A1

  公开（公告）日：2008-09-18

  The present invention provides kinase inhibitors of Formula I:

  本发明提供了化合物I的激酶抑制剂：
• N-(bicyclic heterocyclyl)-4-piperidinamines
  申请人：JANSSEN PHARMACEUTICA N.V.

  公开号：EP0145037A2

  公开（公告）日：1985-06-19

  Novel five membered ring containing N-(bicyclic heterocyclyl)-4-piperidinamines of the formula the pharmaceutically acceptable acid addition salts and possible stereochemically isomeric forms thereof, which compounds are anti-allergic agents; pharmaceutical compositions containing such compounds as an active ingredient and methods of preparing said compounds and pharmaceutical compositions.

  新颖的含 N-(双环杂环)-4-哌啶胺的五元环式 药学上可接受的酸加成盐及其可能的立体化学异构形式，这些化合物是抗过敏剂；含有此类化合物作为活性成分的药物组合物，以及制备所述化合物和药物组合物的方法。
• Vlaovic, Djordje; Canadanovic-Brunet, Jasna; Balaz, Jelica, Bioscience, Biotechnology and Biochemistry, 1992, vol. 56, # 2.3.4., p. 199 - 206
  作者：Vlaovic, Djordje、Canadanovic-Brunet, Jasna、Balaz, Jelica、Juranic, Ivan、Djokovic, Dejan、Mackenzie, Kenneth

  DOI：——

  日期：——